STOCKHOLM, Sweden, June 5 /PRNewswire/ -- Sidec has of today introduced a new version of its Protein Tomography(TM) technology. The new developments drastically improve the analysis of therapeutic antibodies and drug targets in biological systems.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )
Protein Tomography(TM) uses regularization theory to create a 3D image from a series of 2D electron microscope images. The enhanced Protein Tomography(TM) method is developed in order to improve the investigation of the structure and interactions of macromolecules in solution and in cell tissue samples. It does so by speeding up the visualization and analysis steps allowing for rapid identification of binding epitopes and drug-target interactions at the molecular level.
“This new technology will improve both the productivity and the applicability of Protein Tomography(TM) when used to determine e.g. epitopes and will complement existing methods for a better IP strategy and product positioning in the biopharmaceutical industry” Says Anders Aberg CSO at Sidec.
About Sidec AB:
Sidec offers collaborative contract research projects using Protein Tomography(TM) for studying therapeutic antibodies and drug targets in biological systems. The multi-disciplinary team of experts at Sidec can provide a stronger IP strategy and proven product differentiation to the bio-pharmaceutical industry. Protein Tomography(TM) provides our partners with unique visual guidance at the molecular level for target research, lead selection and CD selection to secure a competitive advantage in the drug design strategy.
http://www.sidec.com
CONTACT: For more information, please contact: Hans Johansson, CEO, Phone:
+46(0)8-5600-2102, E-mail: hans.johansson@sidec.com
